YSPSL for Prevention of Delayed Graft Function Part A

This study has been completed.
Sponsor:
Information provided by:
Y's Therapeutics, Inc.
ClinicalTrials.gov Identifier:
NCT00298181
First received: February 27, 2006
Last updated: January 24, 2008
Last verified: January 2008
  Purpose

Selectins have been implicated in the pathogenesis of ischemia/reperfusion (I/R)-induced kidney injury and resultant DGF. PSGL-1 is a ligand for P-, E-, and L-selectin. It has been reported that that YSPSL (rPSGL-Ig) blocks P-selectin and, to a lesser degree, E- and L-selectin. Both sPSGL-1 and YSPSL (rPSGL-Ig) have been shown in animal models to reduce both cytokines and tissue damage associated with ischemia reperfusion and to improve renal function post-transplant. Therefore, the current phase I/II clinical study is designed to assess the safety and efficacy of YSPSL (rPSGL-Ig) in preventing DGF in patients undergoing cadaveric kidney transplants and to determine a dose for future pivotal studies.


Condition Intervention Phase
Delayed Graft Function
Drug: YSPSL
Phase 1
Phase 2

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Controlled, Randomized, Prospective, Double-Blind, Multicenter, Phase I/II, Dose-Escalation Study of the Safety, PK, and Efficacy of YSPSL for Prevention of Delayed Graft Function in Patients Undergoing Cadaveric Kidney Transplantation

Resource links provided by NLM:


Further study details as provided by Y's Therapeutics, Inc.:

Primary Outcome Measures:
  • delayed graft function post transplant [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • renal function parameters through 6 months post transplant [ Time Frame: 6 months ]

Enrollment: 15
Study Start Date: October 2005
Study Completion Date: December 2007
Primary Completion Date: November 2006 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: YSPSL
    YSPSL administered intravenously (IV) as a single bolus infusion open-label at 0.07, 0.22, 0.7 or 2.2 mg/kg
    Other Names:
    • rPSGL-Ig
    • recombinant P-selectin glycoprotein ligand-Ig
Detailed Description:

This will be a multicenter, single-dose, dose-escalation study. The study will be in 2 parts: the first, Part A, will be an open label evaluation of single doses of four dose cohorts and the second, Part B will be a randomized, double-blind, placebo-controlled, single-dose, dose-escalation study of two dose cohorts. Patients who are undergoing cadaveric kidney transplantation and are at risk for development of DGF, based upon known risk factors, will be eligible to participate in the study. A maximum of 24 patients will be enrolled in Part A of the study. 60 patients will be enrolled in Part B.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • primary cadaver renal transplants Other inclusion criteria delineated in protocol

Exclusion Criteria:

  • Full criteria delineated in protocol Patient has a planned transplant of a donor kidney from a non-heartbeating donor; Patient has a planned transplant of kidneys that are implanted en bloc (dual kidney transplant) or from donors <6 years of age; Patient has a planned transplant of a kidney from a donor who has received investigational therapies designed to reduce the impact of ischemia/reperfusion (I/R) injury, DGF, or other donor-related immune events; Patient is planned to receive a living donor kidney; or Patient is planned to receive an ABO-incompatible donor kidney.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00298181

Locations
United States, California
Dumont-UCLA Transplant Center
Los Angeles, California, United States, 90095
California Pacific Medical Center Department of Transplantation
San Francisco, California, United States, 94115
United States, Florida
Lifelink Foundation
Tampa, Florida, United States, 33606
United States, Illinois
Rush University Medical Center
Chicago, Illinois, United States, 60612
United States, New Jersey
Saint Barnabas Medical Center
Livingston, New Jersey, United States, 07039
United States, New York
Westchester Medical Center, New York Medical College
Hawthorne, New York, United States, 10532
United States, Ohio
University of Cincinnati, Department of Internal Medicine
Cincinnati, Ohio, United States, 45267
United States, Tennessee
Methodist Healthcare University Hospital
Memphis, Tennessee, United States, 38104
United States, Texas
Baylor University Medical Center Transplantation Services
Dallas, Texas, United States, 75246
University of Texas, Organ Transplantation
Houston, Texas, United States, 77030
Sponsors and Collaborators
Y's Therapeutics, Inc.
Investigators
Study Director: Stefan Hemmerich, PhD Y's Therapeutics, Inc.
  More Information

No publications provided by Y's Therapeutics, Inc.

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Stefan Hemmerich, PhD, RAC, Y's Therapeutics Inc.
ClinicalTrials.gov Identifier: NCT00298181     History of Changes
Other Study ID Numbers: YSPSL-0001-PF Part A
Study First Received: February 27, 2006
Last Updated: January 24, 2008
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Delayed Graft Function
Pathologic Processes

ClinicalTrials.gov processed this record on July 26, 2014